Florian Rieder1,2, Dominik Bettenworth3, Jin Imai4,5, Yutaka Inagaki4,6. 1. Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland, Ohio, USA. 2. Department of Pathobiology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 3. Department of Medicine B, University Hospital of Münster, Münster, Germany. 4. Center for Matrix Biology and Medicine, Graduate School of Medicine, Tokai University, Isehara, Japan. 5. Department of Gastroenterology, Tokai University School of Medicine, Isehara, Japan. 6. Department of Regenerative Medicine, Tokai University School of Medicine, Isehara, Japan.
Abstract
BACKGROUND: Intestinal fibrosis and liver fibrosis represent a significant burden for our patients and health-care systems. Despite the severe clinical problem and the observation that fibrosis is reversible, no specific antifibrotic therapies exist. SUMMARY: In this review, using an 'East-West' scientific collaboration, we summarize the current knowledge on principal mechanisms shared by intestinal fibrosis and liver fibrosis. We furthermore discuss inflammation as the cause of fibrogenesis in both entities, depict unique features of intestinal and hepatic fibrosis, and provide a future outlook on the development of antifibrotic therapies. KEY MESSAGES: A collaborative effort in the field of fibrosis, covering multiple organ systems, will have the highest chance of leading to the development of a successful antifibrotic intervention.
BACKGROUND: Intestinal fibrosis and liver fibrosis represent a significant burden for our patients and health-care systems. Despite the severe clinical problem and the observation that fibrosis is reversible, no specific antifibrotic therapies exist. SUMMARY: In this review, using an 'East-West' scientific collaboration, we summarize the current knowledge on principal mechanisms shared by intestinal fibrosis and liver fibrosis. We furthermore discuss inflammation as the cause of fibrogenesis in both entities, depict unique features of intestinal and hepatic fibrosis, and provide a future outlook on the development of antifibrotic therapies. KEY MESSAGES: A collaborative effort in the field of fibrosis, covering multiple organ systems, will have the highest chance of leading to the development of a successful antifibrotic intervention.
Entities:
Keywords:
Extracellular matrix; Inflammatory bowel disease; Liver cirrhosis; Organ fibrosis
Authors: Tony Bruns; Jack Peter; Philipp A Reuken; Dominik H Grabe; Sonja R Schuldes; Julia Brenmoehl; Jürgen Schölmerich; Reiner Wiest; Andreas Stallmach Journal: Liver Int Date: 2011-06-13 Impact factor: 5.828
Authors: Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe Journal: Nat Med Date: 2007-10-21 Impact factor: 53.440
Authors: Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo Journal: N Engl J Med Date: 2014-04-11 Impact factor: 91.245